A Randomized Controlled Trial of Nicotinamide Riboside Supplementation in Early Parkinson's Disease

Summary

NOPARK is a double-blinded randomized controlled phase II trial, with the aim to assess the efficacy of nicotinamide adenine dinucleotide (NAD)-replenishment therapy in the form of oral nicotinamide riboside (NR) in delaying the progression of early Parkinson's disease (PD). A total of 400 persons with early stage Parkinson's disease will be enrolled, randomized on nicotinamide riboside (NR) 500mg x 2 per day or placebo, and followed for 52 weeks.

Conditions

• Parkinson Disease

Interventions

DIETARY_SUPPLEMENT

Nicotinamide Riboside

Nicotinamide Riboside 500mg administered two times a day. Given as capsules. Duration of the trial; 52 weeks.

OTHER

Placebo

Placebo drug, administered two times a day. Given as capsules. Duration of the trial; 52 weeks.

Sponsors & Collaborators

• Oslo University Hospital

  collaborator OTHER

• University Hospital, Akershus

  collaborator OTHER

• Ostfold Hospital Trust

  collaborator OTHER

• Førde Hospital Trust

  collaborator OTHER

• Helse Fonna

  collaborator OTHER

• Molde Hospital

  collaborator OTHER

• Bodø sykehus

  collaborator UNKNOWN

• Sorlandet Hospital HF

  collaborator OTHER_GOV

• Drammen sykehus

  collaborator OTHER

• University Hospital of Northern Norway, Tromsø, Norway

  collaborator UNKNOWN

• Haukeland University Hospital

  lead OTHER

Principal Investigators

• Charalampos Tzoulis, MD, PhD · Haukeland University Hospital

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

35 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-05-06

Primary Completion

2025-06-17

Completion

2025-06-17

Countries

• Norway

Study Locations